Does the media refer more to BEAM or DNLI?

In the previous week, Beam Therapeutics had 4 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.45 beat Beam Therapeutics' score of 0.23 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DNLI or BMRN?

In the previous week, BioMarin Pharmaceutical had 6 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for BioMarin Pharmaceutical and 3 mentions for Denali Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Denali Therapeutics' score of 0.45 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNLI or MDGL?

In the previous week, Denali Therapeutics had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 3 mentions for Denali Therapeutics and 2 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Denali Therapeutics' score of 0.45 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DNLI or KRYS?

In the previous week, Denali Therapeutics had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 3 mentions for Denali Therapeutics and 2 mentions for Krystal Biotech. Denali Therapeutics' average media sentiment score of 0.45 beat Krystal Biotech's score of 0.25 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DNLI or KYMR?

In the previous week, Kymera Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Kymera Therapeutics and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.45 beat Kymera Therapeutics' score of 0.34 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Denali Therapeutics (DNLI) Competitors

$20.00 -0.53 (-2.58%)

Closing price 04:00 PM Eastern

Extended Trading

$20.00 +0.00 (+0.02%)

As of 04:21 PM Eastern

Compare

DNLI vs. BEAM, BMRN, MDGL, KRYS, and KYMR

Should you buy Denali Therapeutics stock or one of its competitors? Denali Therapeutics's main competitors and comparable companies include Beam Therapeutics (BEAM), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Krystal Biotech (KRYS), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Denali Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Denali Therapeutics	N/A	-55.27%	-44.24%

Beam Therapeutics presently has a consensus target price of $49.00, suggesting a potential upside of 100.69%. Denali Therapeutics has a consensus target price of $35.85, suggesting a potential upside of 77.29%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Beam Therapeutics has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

Beam Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	18.05	-$79.99M	-$0.86	N/A
Denali Therapeutics	$330.53M	9.78	-$512.54M	-$2.84	N/A

In the previous week, Beam Therapeutics had 4 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.45 beat Beam Therapeutics' score of 0.23 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Beam Therapeutics beats Denali Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to BioMarin Pharmaceutical?

Denali Therapeutics (NASDAQ:DNLI) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

BioMarin Pharmaceutical has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.78	-$512.54M	-$2.84	N/A
BioMarin Pharmaceutical	$3.22B	3.46	$348.90M	$0.37	155.81

In the previous week, BioMarin Pharmaceutical had 6 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for BioMarin Pharmaceutical and 3 mentions for Denali Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Denali Therapeutics' score of 0.45 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Denali Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

Denali Therapeutics presently has a consensus price target of $35.85, suggesting a potential upside of 77.29%. BioMarin Pharmaceutical has a consensus price target of $89.17, suggesting a potential upside of 54.68%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Denali Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.67

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Denali Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Summary

BioMarin Pharmaceutical beats Denali Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Madrigal Pharmaceuticals?

Denali Therapeutics (NASDAQ:DNLI) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Madrigal Pharmaceuticals has higher revenue and earnings than Denali Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.78	-$512.54M	-$2.84	N/A
Madrigal Pharmaceuticals	$958.40M	11.95	-$288.28M	-$12.89	N/A

Denali Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, indicating that its stock price is 204% less volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Denali Therapeutics' return on equity of -55.27% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Denali Therapeutics currently has a consensus target price of $35.85, suggesting a potential upside of 77.29%. Madrigal Pharmaceuticals has a consensus target price of $710.20, suggesting a potential upside of 43.24%. Given Denali Therapeutics' higher possible upside, equities research analysts clearly believe Denali Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Denali Therapeutics had 1 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 3 mentions for Denali Therapeutics and 2 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.57 beat Denali Therapeutics' score of 0.45 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Madrigal Pharmaceuticals beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Krystal Biotech?

Denali Therapeutics (NASDAQ:DNLI) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, Denali Therapeutics had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 3 mentions for Denali Therapeutics and 2 mentions for Krystal Biotech. Denali Therapeutics' average media sentiment score of 0.45 beat Krystal Biotech's score of 0.25 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.78	-$512.54M	-$2.84	N/A
Krystal Biotech	$389.13M	24.98	$204.83M	$7.98	41.15

Denali Therapeutics presently has a consensus price target of $35.85, indicating a potential upside of 77.29%. Krystal Biotech has a consensus price target of $377.20, indicating a potential upside of 14.87%. Given Denali Therapeutics' higher probable upside, equities research analysts clearly believe Denali Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Denali Therapeutics has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Denali Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.34% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Krystal Biotech	54.82%	19.34%	17.65%

Summary

Krystal Biotech beats Denali Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Kymera Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Denali Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

Denali Therapeutics presently has a consensus price target of $35.85, indicating a potential upside of 77.29%. Kymera Therapeutics has a consensus price target of $133.21, indicating a potential upside of 21.76%. Given Denali Therapeutics' higher possible upside, research analysts clearly believe Denali Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88

92.9% of Denali Therapeutics shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kymera Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.78	-$512.54M	-$2.84	N/A
Kymera Therapeutics	$39.21M	232.00	-$311.35M	-$3.24	N/A

In the previous week, Kymera Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Kymera Therapeutics and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.45 beat Kymera Therapeutics' score of 0.34 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Denali Therapeutics has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

Summary

Kymera Therapeutics beats Denali Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNLI vs. The Competition

Export

Metric	Denali Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.20B	$3.84B	$7.11B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-7.04	13.44	274.42	26.03
Price / Sales	9.67	1,285.38	600.72	89.51
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	2.89	16.64	10.92	6.32
Net Income	-$512.54M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-1.91%	-2.99%	-2.07%	-1.66%
1 Month Performance	-12.47%	-10.68%	-6.32%	-3.93%
1 Year Performance	31.58%	21.44%	8.92%	2.82%

Denali Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNLI Denali Therapeutics	2.6824 of 5 stars	$20.00 -2.6%	$35.85 +79.2%	+37.7%	$3.20B	$330.53M	N/A	507
BEAM Beam Therapeutics	2.5915 of 5 stars	$25.26 +1.2%	$49.00 +94.0%	+1.1%	$2.58B	$139.74M	N/A	540	Gap Up
BMRN BioMarin Pharmaceutical	4.4597 of 5 stars	$64.06 +0.2%	$89.17 +39.2%	+6.5%	$12.38B	$3.22B	173.14	3,221	Trending News
MDGL Madrigal Pharmaceuticals	3.0237 of 5 stars	$521.96 -1.8%	$699.64 +34.0%	+11.3%	$12.28B	$958.40M	N/A	915
KRYS Krystal Biotech	4.0372 of 5 stars	$333.85 -0.8%	$365.80 +9.6%	+81.1%	$9.97B	$389.13M	41.84	295

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNLI) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, BMRN, MDGL, KRYS, and KYMR

How does Denali Therapeutics compare to Beam Therapeutics?

Summary

How does Denali Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Denali Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Denali Therapeutics compare to Krystal Biotech?

Summary

How does Denali Therapeutics compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, BMRN, MDGL, KRYS, and KYMR

How does Denali Therapeutics compare to Beam Therapeutics?

Do insiders and institutionals hold more shares of BEAM or DNLI?

Is BEAM or DNLI more profitable?

Do analysts recommend BEAM or DNLI?

Which has more risk & volatility, BEAM or DNLI?

Which has better earnings & valuation, BEAM or DNLI?

Does the media refer more to BEAM or DNLI?

Summary

How does Denali Therapeutics compare to BioMarin Pharmaceutical?

Which has preferable earnings & valuation, DNLI or BMRN?

Does the media prefer DNLI or BMRN?

Which has more volatility and risk, DNLI or BMRN?

Do analysts prefer DNLI or BMRN?

Do insiders & institutionals believe in DNLI or BMRN?

Is DNLI or BMRN more profitable?

Summary

How does Denali Therapeutics compare to Madrigal Pharmaceuticals?

Do institutionals and insiders believe in DNLI or MDGL?

Which has stronger valuation & earnings, DNLI or MDGL?

Which has more risk & volatility, DNLI or MDGL?

Is DNLI or MDGL more profitable?

Do analysts rate DNLI or MDGL?

Does the media prefer DNLI or MDGL?

Summary

How does Denali Therapeutics compare to Krystal Biotech?

Does the media refer more to DNLI or KRYS?

Which has stronger valuation & earnings, DNLI or KRYS?

Do analysts recommend DNLI or KRYS?

Do insiders and institutionals have more ownership in DNLI or KRYS?

Which has more volatility and risk, DNLI or KRYS?

Is DNLI or KRYS more profitable?

Summary

How does Denali Therapeutics compare to Kymera Therapeutics?

Is DNLI or KYMR more profitable?

Do analysts rate DNLI or KYMR?

Do institutionals & insiders have more ownership in DNLI or KYMR?

Which has higher valuation & earnings, DNLI or KYMR?

Does the media prefer DNLI or KYMR?

Which has more volatility and risk, DNLI or KYMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools